What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2023-08-07 compared with 2023-05-05 · 129 added, 71 removed, 195 unchanged (51% of the section changed)

1 unchanged sentence

The following is a discussion and analysis of the financial condition of AbbVie Inc.

(AbbVie or the company) as of March 31, 2023 and December 31, 2022 and the results of operations for the three months ended March 31, 2023 and 2022.

(AbbVie or the company) as of June 30, 2023 and December 31, 2022 and the results of operations for the three and six months ended June 30, 2023 and 2022.

This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”

18 unchanged sentences

Financial Results

The company's financial performance for the three months ended March 31, 2023 included delivering worldwide net revenues of $12.2 billion, operating earnings of $2.8 billion, diluted earnings per share of $0.13 and cash flows from operations of $4.2 billion.

The company's financial performance for the six months ended June 30, 2023 included delivering worldwide net revenues of $26.1 billion, operating earnings of $7.3 billion, diluted earnings per share of $1.26 and cash flows from operations of $10.5 billion.

Worldwide net revenues decreased 7% on a reported basis and 6% on a constant currency basis.

Diluted earnings per share was $0.13 for the three months ended March 31, 2023 and included the following after-tax costs:

(i) $1.8 billion for the change in fair value of contingent consideration liabilities;

(ii) $1.6 billion related to the amortization of intangible assets;

(iii) $629 million related to intangible asset impairment;

and (iv) $55 million of acquisition and integration expenses.

Diluted earnings per share was $1.26 for the six months ended June 30, 2023 and included the following after-tax costs:

(i) $3.4 billion related to the amortization of intangible assets;

(ii) $3.3 billion for the change in fair value of contingent consideration liabilities;

and (iii) $629 million related to intangible asset impairment.

Additionally, financial results reflected continued funding to support all stages of AbbVie’s pipeline assets and continued investment in AbbVie’s on-market brands.

2 unchanged sentences

AbbVie’s long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.

AbbVie’s pipeline currently includes over 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.

AbbVie’s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.

Of these programs, over 50 are in mid- and late-stage development.

3 unchanged sentences

Significant Programs and Developments

• In March 2023, the European Commission (EC) issued their final decision on the European Medicines Agency’s review of the benefit-risk of medicines in the JAK inhibitor class for the treatment of inflammatory diseases, including Rinvoq.

Confirming the Committee for Medicinal Products for Human Use opinion, the previously approved Rinvoq indication statements were not changed and the dosage and special warnings for all JAK inhibitors were updated to include additional information about the risks associated with JAK inhibitors.

• In March 2023, the European Commission (EC) issued their final decision on the European Medicines Agency’s (EMA) review of the benefit-risk of medicines in the JAK inhibitor class for the treatment of inflammatory diseases, including Rinvoq.

Confirming the Committee for Medicinal Products for Human Use (CHMP) opinion, the previously approved Rinvoq indication statements were not changed and the dosage and special warnings for all JAK inhibitors were updated to include additional information about the risks associated with JAK inhibitors.

• In April 2023, AbbVie announced that the EC approved Rinvoq for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

• In May 2023, AbbVie announced that the U.S.

Food and Drug Administration (FDA) approved Rinvoq for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

• In July 2023, AbbVie initiated its Phase 3 Step-Up HS study to evaluate efficacy and safety of Rinvoq in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-TNF therapy and/or one approved non-anti-TNF inhibitor therapy for HS.

• In March 2023, AbbVie announced positive top-line results from its Phase 3 induction study, INSPIRE, for Skyrizi in patients with moderately to severely active ulcerative colitis met the primary and all secondary endpoints.

• In March 2023, AbbVie initiated a Phase 3 clinical trial to evaluate epcoritamab in combination with R-CHOP compared to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.

• In April 2023, AbbVie announced the intent to voluntarily withdraw, in the U.S., accelerated Imbruvica approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

This voluntary action is due to requirements rel ated to the accelerated approval status granted by the U.S.

Food and Drug Administration (FDA) for MCL and MZL.

• In June 2023, AbbVie announced positive top-line results from its Phase 3 maintenance study, COMMAND, for Skyrizi in patients with moderately to severely active ulcerative colitis met the primary and key secondary endpoints.

• In July 2023, AbbVie announced results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi compared to Otezla among adult patients with moderate plaque psoriasis (PsO) eligible for systemic therapy.

In the study, significantly more patients achieved co-primary endpoints with Skyrizi versus Otezla.

Skyrizi was well-tolerated with no new safety signals identified.

• In March 2023, AbbVie initiated a Phase 3 clinical trial to evaluate epcoritamab in combination with R-CHOP compared to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

• In May 2023, AbbVie announced that the FDA approved Epkinly (epcoritamab) as the first and only bispecific antibody to treat adult patients with relapsed or refractory (R/R) DLBCL.

• In July 2023, AbbVie announced that the CHMP of the EMA has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab as a monotherapy for the treatment of adult patients with R/R DLBCL after two or more lines of systemic therapy.

• In May 2023, AbbVie voluntarily withdrew, in the U.S., accelerated Imbruvica approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

This voluntary action is due to requirements rel ated to the accelerated approval status granted by the FDA for MCL and MZL.

Other approved indications for Imbruvica in the U.S.

are not affected.

2023 Form 10-Q |

• In July 2023, AbbVie announced top-line results from the Phase 3 TRANSFORM-1 clinical trial evaluating the safety and efficacy of navitoclax, a BCL-XL/BCL-2 inhibitor, in combination with ruxolitinib in adult patients with primary or secondary myelofibrosis (MF).

The combination of navitoclax and ruxolitinib met the study’s primary endpoint, demonstrating statistically significant improvement in the number of patients who achieved Spleen Volume Reduction of at least 35 percent at week 24 compared to treatment with ruxolitinib and a placebo.

The study did not meet the first ranked secondary endpoint of improvement in patients’ Total Symptom Score from baseline to week 24.

The company plans to wait for additional follow up data on the primary, secondary and other endpoints, expected in the fourth quarter of this year, before engaging with regulatory agencies regarding potential next steps.

Juvederm Collection

• In May 2023, AbbVie announced that the FDA approved Skinvive by Juvederm to improve skin smoothness of the cheeks in adults over the age of 21.

• In March 2023, AbbVie announced that the FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

2 unchanged sentences

• In April 2023, A bbVie announced that the FDA approved Qulipta for the preventive treatment of chronic migraine in adults.

• In June 2023, AbbVie announced that the CHMP of the EMA has adopted a positive opinion recommending the approval of Qulipta for the prophylaxis of migraine in adults who have four or more migraine days per month.

For a more comprehensive discussion of AbbVie’s products and pipeline, see the company’s Annual Report on Form 10-K for the year ended December 31, 2022.

5 unchanged sentences

Three months ended

March 31, Percent change

June 30, Percent change Six months ended

June 30, Percent change

currency rates At constant

currency rates At actual

currency rates At constant

currency rates

(dollars in millions)

2023 2022 2023 2022

United States

6 unchanged sentences

Three months ended

March 31, Percent change

June 30, Percent change Six months ended

June 30, Percent change

currency rates At constant

currency rates At actual

currency rates At constant

currency rates

(dollars in millions)

2023 2022 2023 2022

Humira United States $ 3,452 $ 4,664 (26.0) % (26.0) % $ 6,400 $ 8,657 (26.1) % (26.1) %

27 unchanged sentences

Vraylar United States $ 657 $ 492 33.7 % 33.7 % $ 1,217 $ 919 32.5 % 32.5 %

International 1 — n/m n/m

International 1 — >100.0 % >100.0 % 2 — >100.0 % >100.0 %

Total $ 658 $ 492 33.9 % 33.9 % $ 1,219 $ 919 32.7 % 32.7 %

3 unchanged sentences

Ubrelvy United States $ 194 $ 185 4.5 % 4.5 % $ 344 $ 323 6.4 % 6.4 %

International 2 — n/m n/m

International 2 — n/m n/m 4 — n/m n/m

Total $ 196 $ 185 5.9 % 6.0 % $ 348 $ 323 7.7 % 7.7 %

Qulipta United States $ 95 $ 33 >100.0 % >100.0 % $ 161 $ 44 >100.0 % >100.0 %

International 1 — n/m n/m 1 — n/m n/m

Total $ 96 $ 33 >100.0 % >100.0 % $ 162 $ 44 >100.0 % >100.0 %

Other Neuroscience United States $ 65 $ 145 (55.9) % (55.9) % $ 140 $ 318 (56.3) % (56.3) %

3 unchanged sentences

Three months ended

March 31, Percent change

June 30, Percent change Six months ended

June 30, Percent change

currency rates At constant

currency rates At actual

currency rates At constant

currency rates

(dollars in millions)

2023 2022 2023 2022

Ozurdex United States $ 34 $ 36 (3.3) % (3.3) % $ 73 $ 69 6.3 % 6.3 %

25 unchanged sentences

The following discussion and analysis of AbbVie’s net revenues by product is presented on a constant currency basis.

Global Humira sales decreased 24% for the three months ended March 31, 2023.

In the United States, Humira sales decreased by 26% for the three months ended March 31, 2023 primarily driven by direct biosimilar competition following the loss of exclusivity on January 31, 2023.

Internationally, Humira revenues decreased 15% for the three months ended March 31, 2023 primarily driven by the continued impact of direct biosimilar competition.

Global Humira sales decreased 25% for the three and six months ended June 30, 2023.

In the United States, Humira sales decreased by 26% for the three and six months ended June 30, 2023 primarily driven by direct biosimilar competition following the loss of exclusivity on January 31, 2023.

Internationally, Humira revenues decreased 17% for the three months and 16% for the six months ended June 30, 2023 primarily driven by the continued impact of direct biosimilar competition.

AbbVie continues to pursue strategies to maintain broad formulary access of Humira and manage the impact of biosimilar erosion.

Net revenues for Skyrizi increased 46% for the three months ended March 31, 2023 primarily driven by continued strong volume and market share uptake as well as market growth across all indications, partially offset by unfavorable pricing and the timing of retail inventory destocking.

Net revenues for Rinvoq increased 51% for the three months ended March 31, 2023 primarily driven by continued strong volume and market share uptake as well as market growth across all indications, partially offset by unfavorable pricing and the timing of retail inventory destocking.

Net revenues for Skyrizi increased 51% for the three months and 49% for the six months ended June 30, 2023 primarily driven by continued strong volume and market share uptake as well as market growth across all indications, partially offset by unfavorable pricing.

Net revenues for Rinvoq increased 57% for the three months and 54% for the six months ended June 30, 2023 primarily driven by continued strong volume and market share uptake as well as market growth across all indications, partially offset by unfavorable pricing.

Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie’s 50% share of Imbruvica profit.

AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2023 primarily driven by decreased demand and lower market share in the United States as well as decreased collaboration revenues.

Net revenues for Venclexta increased 18% for the three months ended March 31, 2023 primarily driven by continued volume and market share uptake across all indications as well as favorable pricing.

Net revenues for Botox Cosmetic increased 6% for the three months ended March 31, 2023 primarily driven by increased market penetration in key international markets, partially offset by decreased consumer demand in the Unites States due to economic pressures impacting consumer discretionary spending.

AbbVie's global Imbruvica revenues decreased 21% for the three months and 23% for the six months ended June 30, 2023 primarily driven by decreased demand and lower market share in the United States as well as decreased collaboration revenues.

Net revenues for Venclexta increased 15% for the three months and 16% for the six months ended June 30, 2023 primarily driven by market growth across all indications as well as favorable pricing.

Internationally, net revenues for the three and six months ended June 30, 2023 were also favorably impacted by continued volume and market share uptake.

Net revenues for Botox Cosmetic increased 1% for the three months and 3% for the six months ended June 30, 2023.

Internationally, Botox Cosmetic net revenues increased 14% for the three months and 16% for the six months ended June 30, 2023 primarily driven

2023 Form 10-Q |

Net revenues for Juvederm Collection decreased 7% for the three months ended March 31, 2023 primarily driven by decreased consumer demand in the United States due to economic pressures impacting consumer discretionary spending.

Net revenues for Botox Therapeutic increased 19% for the three months ended March 31, 2023 primarily driven by market growth and the timing of shipments.

Net revenues for Vraylar increased 31% for the three months ended March 31, 2023 primarily driven by continued volume and market share uptake as well as market growth.

Net revenues for Ubrelvy increased 10% for the three months ended March 31, 2023 primarily driven by continued volume and market share uptake as well as market growth.

Net revenues for Qulipta increased greater than 100% for the three months ended March 31, 2023 primarily driven by continued strong volume and market share uptake since launch for the preventative treatment of episodic migraine in adults.

by increased investment in key markets, including Asia and Latin America, and recovery from COVID-19 in China.

In the United States, Botox Cosmetic net revenues decreased 7% for the three months and 4% for the six months ended June 30, 2023 primarily driven by decreased consumer demand and unfavorable pricing due to economic pressures impacting consumer discretionary spending.

Net revenues for Juvederm Collection increased 10% for the three months ended June 30, 2023 and remained flat for the six months ended June 30, 2023.

Internationally, Juvederm Collection net revenues increased 28% for the three months and 11% for the six months ended June 30, 2023 primarily driven by increased investment in key markets, including Asia and Latin America, and recovery from COVID-19 in China.

In the United States, Juvederm Collection net revenues decreased 15% for the three months and 16% for the six months ended June 30, 2023 primarily driven by decreased consumer demand due to economic pressures impacting consumer discretionary spending.

Net revenues for Botox Therapeutic increased 11% for the three months and 15% for the six months ended June 30, 2023 primarily driven by market growth as well as market share uptake.

Net revenues for the six months ended June 30, 2023 were also favorably impacted by the timing of shipments.

Net revenues for Vraylar increased 34% for the three months and 33% for the six months ended June 30, 2023 primarily driven by continued volume and market share uptake as well as market growth.

Net revenues for the three and six months ended June 30, 2023 were also favorably impacted by the recent regulatory approval of Vraylar as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.

Net revenues for Ubrelvy increased 6% for the three months and 8% for the six months ended June 30, 2023 primarily driven by continued volume and market share uptake as well as market growth.

Net revenues for Qulipta increased greater than 100% for the three and six months ended June 30, 2023 primarily driven by continued strong volume and market share uptake as well as market growth.

Net revenues for the three months ended June 30, 2023 were also favorably impacted by the recent regulatory approval of Qulipta for the preventative treatment of chronic migraine in adults.

Three months ended

(dollars in millions) 2023 2022 % change

June 30, Six months ended

(dollars in millions) 2023 2022 % change 2023 2022 % change

Gross margin $ 9,625 $ 10,413 (8) % $ 17,864 $ 19,899 (10) %

as a % of net revenues 69 % 71 % 68 % 71 %

Gross margin as a percentage of net revenues decreased for the three months ended March 31, 2023 compared to the prior year.

Gross margin percentage for the three months ended March 31, 2023 was unfavorably impacted by higher amortization of intangible assets and changes in product mix.

Gross margin as a percentage of net revenues decreased for the three and six months ended June 30, 2023 compared to the prior year.

Gross margin percentage for the three and six months ended June 30, 2023 was unfavorably impacted by higher amortization of intangibles and changes in product mix, partially offset by the favorable impact of tax law changes in Puerto Rico.

Selling, General and Administrative

Three months ended

(dollars in millions) 2023 2022 % change

June 30, Six months ended

(dollars in millions) 2023 2022 % change 2023 2022 % change

Selling, general and administrative $ 3,268 $ 5,412 (40) % $ 6,307 $ 8,539 (26) %

as a % of net revenues 24 % 37 % 24 % 30 %

Selling, general and administrative (SG&A) expenses decreased for the three months ended March 31, 2023 compared to the prior year primarily driven by lower litigation reserve charges.

SG&A expenses as a percentage of net revenues increased for the three months ended March 31, 2023 compared to the prior year.

SG&A expense percentage was unfavorably impacted by lower net revenues primarily driven by the Humira loss of exclusivity in the United States.

Research and Development and Acquired IPR&D and Milestones

SG&A expenses as a percentage of net revenues decreased for the three and six months ended June 30, 2023 compared to the prior year.

SG&A expense percentage was favorably impacted by lower litigation reserve charges for the three and six months ended June 30, 2023 as compared to the prior year.

Litigation reserve charges were $2.2 billion for the three months and $2.4 billion for the six months ended June 30, 2022.

The decrease in SG&A expense percentage for the three and six months ended June 30, 2023 was partially offset by the unfavorable impact of lower net revenues primarily driven by the Humira loss of exclusivity in the United States.

2023 Form 10-Q |

Research and Development

Three months ended

(dollars in millions) 2023 2022 % change

June 30, Six months ended

(dollars in millions) 2023 2022 % change 2023 2022 % change

Research and development $ 1,733 $ 1,609 8 % $ 4,025 $ 3,106 30 %

as a % of net revenues 12 % 11 % 15 % 11 %

Research and development (R&D) expenses as a percentage of net revenues increased for the three and six months ended June 30, 2023 compared to the prior year.

R&D expense percentage for the three and six months ended June 30, 2023 was unfavorably impacted by increased funding to support all stages of the company’s pipeline assets and lower net revenues primarily driven by the Humira loss of exclusivity in the United States.

R&D expense percentage for the six months ended June 30, 2023 was also unfavorably impacted by an intangible asset impairment charge of $630 million.

Acquired IPR&D and Milestones

Research and development (R&D) expenses as a percentage of net revenues increased for the three months ended March 31, 2023 compared to the prior year.

R&D expense percentage for the three months ended March 31, 2023 was unfavorably impacted by an intangible asset impairment charge of $630 million.

Acquired IPR&D and milestones expense in the three months ended March 31, 2023 included charges related to upfront payments of $132 million and development milestones of $18 million.

Acquired IPR&D and milestones expense in the three months ended March 31, 2022 included a charge of $130 million related to acquiring Syndesi Therapeutics SA and development milestones of $15 million.

2023 Form 10-Q |

Three months ended

June 30, Six months ended

(dollars in millions) 2023 2022 2023 2022

Upfront charges $ 220 $ 222 $ 352 $ 352

Development milestones 60 47 78 62

Acquired IPR&D and milestones $ 280 $ 269 $ 430 $ 414

Acquired IPR&D and milestones expense for the six months ended June 30, 2022 included a charge related to the upfront payment of $130 million to acquire Syndesi Therapeutics SA.

See Note 4 to the Condensed Consolidated Financial Statements for additional information.

Other Operating Income

Other operating income for the three and six months ended June 30, 2023 included a one-time gain of $169 million related to the termination of a development liability associated with a previously divested product.

Ot her operating income for the three and six months ended June 30, 2022 included $172 million of income related to the sale of worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobactor pylori.

See Note 4 to the Condensed Consolidated Financial Statements for additional information.

Other Non-Operating Expenses (Income)

Three months ended

June 30, Six months ended

(in millions) 2023 2022 2023 2022

3 unchanged sentences

Net foreign exchange loss $ 37 $ 47 $ 72 $ 72

Other expense (income), net 1,804 (776)

Interest expense increased for the three months ended March 31, 2023 compared to the prior year primarily due to the impact of higher interest rates, partially offset by lower average debt balance as a result of deleveraging.

Interest income increased for the three months ended March 31, 2023 compared to the prior year primarily due to the impact of higher interest rates.

Other expense (income), net included a charge related to changes in fair value of contingent consideration liabilities of $1.9 billion for the three months ended March 31, 2023 and a benefit of $748 million for the three months ended March 31, 2022.

Other expense, net 1,412 1,533 3,216 757

Interest expense remained flat for the three and six months ended June 30, 2023 compared to the prior year primarily driven by the impact of higher interest rates, offset by lower average debt balances as a result of deleveraging.

Interest income increased for the three and six months ended June 30, 2023 compared to the prior year primarily due to the impact of higher interest rates.

Other expense, net included charges related to changes in fair value of contingent consideration liabilities of $1.6 billion for the three months and $3.4 billion for the six months ended June 30, 2023 and $1.6 billion for the three months and $861 million for the six months ended June 30, 2022.

The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors.

For the three months ended March 31, 2023, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake, the passage of time, lower discount rates and favorable clinical trial results.

For the three months ended March 31, 2022 the change in fair value was driven by higher discount rates partially offset by the passage of time.

For the three and six months ended June 30, 2023, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake and the passage of time.

The change in fair value for the three months ended June 30, 2023 is also partially offset by higher discount rates.

For the three and six

2023 Form 10-Q |

months ended June 30, 2022 the change in fair value represented higher estimated Skyrizi sales driven by stronger market share uptake, partially offset by higher discount rates.

Income Tax Expense

The effective tax rate was 49% for the three months ended March 31, 2023 compared to 9% for the three months ended March 31, 2022.

The effective tax rate was 22% for the three months and 26% for the six months ended June 30, 2023 compared to 22% for the three months and 11% for the six months ended June 30, 2022.

The effective tax rate in each period differed from the U.S.

statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, changes in fair value of contingent consideration and business development activities.

The increase in the effective tax rate for the three months ended March 31, 2023 over the prior year was primarily due to changes in fair value of contingent consideration, tax law changes in Puerto Rico and impairment of certain intangible assets.

The increase in the effective tax rate for the six months ended June 30, 2023 over the prior year was primarily due to changes in fair value of contingent consideration, tax law changes in Puerto Rico and impairment of certain intangible assets.

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

Three months ended

Six months ended

(in millions) 2023 2022

3 unchanged sentences

Financing activities (10,112) (9,651)

Operating cash flows for the three months ended March 31, 2023 decreased compared to the prior year primarily due to decreased results of operations primarily driven by lower net revenues, partially offset by the timing of working capital.

Investing cash flows for the three months ended March 31, 2023 included payments made for acquisitions and investments of $353 million and capital expenditures of $175 million.

Investing cash flows for the three months ended March 31, 2022 included payments made for net purchases of investment securities totaling $1.4 billion, acquisitions and investments of $185 million and capital expenditures of $162 million.

Financing cash flows for the three months ended March 31, 2023 included repayments of $1.0 billion floating rate term loan and $350 million aggregate principal amount of the company’s 2.80% senior notes.

Financing cash flows for the three months ended March 31, 2022 included a repayment of $2.9 billion aggregate principal amount of the company’s 3.45% senior notes.

Additionally, financing cash flows for the three months ended March 31, 2022 included a repayment of $2.0 billion floating rate term loan due May 2025 and issuance of a new $2.0 billion floating rate term loan as part of the term loan refinancing in February 2022.

2023 Form 10-Q |

Financing cash flows also included cash dividend payments of $2.7 billion for the three months ended March 31, 2023 and $2.5 billion for the three months ended March 31, 2022.

Operating cash flows for the six months ended June 30, 2023 increased compared to the prior year due to the timing of working capital partially offset by decreased results of operations primarily driven by lower net revenues as well as higher payments for income taxes.

Investing cash flows for the six months ended June 30, 2023 included payments made for acquisitions and investments of $513 million and capital expenditures of $353 million.

Investing cash flows for the six months ended June 30, 2022 included payments made for net purchases of investment securities totaling $1.4 billion, acquisitions and investments of $394 million and capital expenditures of $305 million.

Financing cash flows for the six months ended June 30, 2023 included repayments of $1.0 billion floating rate term loan, $1.0 billion aggregate principal amount of 2.85% senior notes and $350 million aggregate principal amount of the company’s 2.80% senior notes.

Financing cash flows for the six months ended June 30, 2022 included a repayment of $2.9 billion aggregate principal amount of the company’s 3.45% senior notes.

Additionally, financing cash flows for the six months ended June 30, 2022 included a repayment of $2.0 billion floating rate term loan due May 2025 and issuance of a new $2.0 billion floating rate term loan as part of the term loan refinancing in February 2022.

Financing cash flows also included cash dividend payments of $5.3 billion for the six months ended June 30, 2023 and $5.0 billion for the six months ended June 30, 2022.

The increase in cash dividend payments was primarily driven by the increase in the quarterly dividend rate.

On February 16, 2023, the company announced that its board of directors declared a quarterly cash dividend of $1.48 per share for stockholders of record at the close of business on April 14, 2023, payable on May 15, 2023.

On June 22, 2023, the company announced that its board of directors declared a quarterly cash dividend of 1.48 per share for stockholders of record at the close of business on July 14, 2023, payable on August 15, 2023.

The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie’s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie’s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.

2 unchanged sentences

On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization.

AbbVie repurchased 10 million shares for $1.6 billion during the three months ended March 31, 2023 and 8 million shares for $1.1 billion during the three months ended March 31, 2022.

AbbVie repurchased 10 million shares for $1.6 billion during the six months ended June 30, 2023 and 8 million shares for $1.1 billion during the six months ended June 30, 2022.

AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad.

AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables.

AbbVie establishes an allowance for credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable.

AbbVie establishes an allowance for credit

2023 Form 10-Q |

losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable.

AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.

4 unchanged sentences

This credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants.

At March 31, 2023, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant.

No amounts were outstanding under the company's credit facility as of March 31, 2023 and December 31, 2022.

At June 30, 2023, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant.

No amounts were outstanding under the company's credit facility as of June 30, 2023 and December 31, 2022.

Access to Capital

3 unchanged sentences

Credit Ratings

There were no changes in the company’s credit ratings during the three months ended March 31, 2023.

There were no changes in the company’s credit ratings during the six months ended June 30, 2023.

Unfavorable changes to the ratings may have an adverse impact on future financing arrangements;

2 unchanged sentences

A summary of the company’s significant accounting policies is included in Note 2, “Summary of Significant Accounting Policies” in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2022.

There have been no significant changes in the company’s application of its critical accounting policies during the three months ended March 31, 2023.

2023 Form 10-Q |

There have been no significant changes in the company’s application of its critical accounting policies during the six months ended June 30, 2023.

FORWARD-LOOKING STATEMENTS

8 unchanged sentences

For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2022.

2023 Form 10-Q |

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis